Accession Number : AD1011879


Title :   The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase 3 Clinical Trial in Ovarian Cancer


Descriptive Note : Technical Report,30 Sep 2013,29 Sep 2015


Corporate Author : University of Washington Seattle United States


Personal Author(s) : Swisher,Elizabeth


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1011879.pdf


Report Date : 01 Dec 2014


Pagination or Media Count : 45


Abstract : The Gynecologic Oncology Group (GOG) trial 218 was a randomized phase III trial in primary stage III and IV ovarian carcinoma, which found a statistically significant improvement in progression free survival (PFS) for combination chemotherapy with extended bevacizumab, an antibody to the VEGF receptor that inhibits angiogenesis. We deeply sequences 65 DNA repair genes in germline and/or tumor DNA from GOG218 and another upfront clinical trial GOG262. We found that germline or somatic mutations in the BRCA-Fanconi anemia pathway was significantly associated with improved progression-free and overall survival. Moreover, the presence of inherited mutations was not limited to high grade serous carcinomas but was found in most histological sub-type. Finally, we did not identify an interaction between the presence of a BRCA-Fanconi anemia mutation and benefit from bevacizumab in GOG218.


Descriptors :   BREAST CANCER , histology , oncology , drug therapy , neoplasms , clinical trials , therapeutics , chemotherapy , statistical analysis , carcinoma , mutations


Distribution Statement : APPROVED FOR PUBLIC RELEASE